EVX 020 - Evexta Bio
Alternative Names: DIACC-2020; EVX-020Latest Information Update: 08 Jan 2024
At a glance
- Originator Diaccurate
- Developer Evexta Bio
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Kinesin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Solid tumours